0000000000224849

AUTHOR

María-laura Fox

showing 2 related works from this author

Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study.

2020

Abstract Patients with Philadelphia-negative myeloproliferative neoplasm (MPN) are prone to the development of second cancers, but the factors associated with these events have been poorly explored. In an international nested case-control study, we recruited 647 patients with carcinoma, nonmelanoma skin cancer, hematological second cancer, and melanoma diagnosed concurrently or after MPN diagnosis. Up to 3 control patients without a history of cancer and matched with each case for center, sex, age at MPN diagnosis, date of diagnosis, and MPN disease duration were included (n = 1234). Cases were comparable to controls for MPN type, driver mutations and cardiovascular risk factors. The freque…

medicine.medical_specialtyImmunologyKaplan-Meier EstimateGene mutationBiochemistryGastroenterologyMyeloproliferative neoplasms03 medical and health sciences0302 clinical medicineSDG 3 - Good Health and Well-beingInternal medicineCarcinomaMedicineHumansPhiladelphia ChromosomeMyeloproliferative neoplasmMyeloproliferative Disordersbusiness.industryCase-control studyCancerfood and beveragesMyeloproliferative neoplasmssecond cancersarterial eventsNeoplasms Second PrimaryThrombosisCell BiologyHematologyOdds ratioArteriesmedicine.diseasesecond cancersThrombosisSettore MED/15 - MALATTIE DEL SANGUEarterial events030220 oncology & carcinogenesisCase-Control StudiesMultivariate Analysis/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingSkin cancerbusiness030215 immunologyFollow-Up StudiesBlood
researchProduct

Predicting Survival after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: Performance of the Myelofibrosis Transplant Scoring System …

2020

Accurate prognostic tools are crucial to assess the risk/benefit ratio of allogeneic hematopoietic cell transplantation (allo-HCT) in patients with myelofibrosis (MF). We aimed to evaluate the performance of the Myelofibrosis Transplant Scoring System (MTSS) and identify risk factors for survival in a multicenter series of 197 patients with MF undergoing allo-HCT. After a median follow-up of 3.1 years, 47% of patients had died, and the estimated 5 year survival rate was 51%. Projected 5-year risk of nonrelapse mortality and relapse incidence was 30% and 20%, respectively. Factors independently associated with increased mortality were a hematopoietic cell transplantation-specific comorbidity…

Oncologymedicine.medical_specialtyTransplantation ConditioningScoring systemCyclophosphamideSurvivalMyelofibrosisPrognostication03 medical and health sciences0302 clinical medicineMyelofibrosis Prognostication Risk factors Survival TransplantationInternal medicineHumansTransplantation HomologousMedicineMyelofibrosisSurvival rateTransplantationFramingham Risk Scorebusiness.industryIncidence (epidemiology)Hematopoietic Stem Cell TransplantationHematologyPrognosismedicine.diseaseTransplantationTreatment OutcomeRisk factorsPrimary Myelofibrosis030220 oncology & carcinogenesisCord bloodbusiness030215 immunologymedicine.drug
researchProduct